PriceTargets.com logo

Novozymes A/S - NVZMY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $370.00
  • Forecasted Upside: 635.74%
  • Number of Analysts: 10
  • Breakdown:
  • 2 Sell Ratings
  • 7 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$50.29 As of 03/23/2023 01:00 AM ET
▲ +0.04 (0.08%)

This chart shows the closing price for NVZMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novozymes A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVZMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVZMY

Analyst Price Target is $370.00
▲ +635.74% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Novozymes A/S in the last 3 months. The average price target is $370.00, with a high forecast of $370.00 and a low forecast of $370.00. The average price target represents a 635.74% upside from the last price of $50.29.

This chart shows the closing price for NVZMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in Novozymes A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/20/2023Credit Suisse GroupUpgradeUnderperform ➝ Neutral
12/16/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
12/13/2022BarclaysDowngradeOverweight ➝ Equal Weight
12/13/2022DNB MarketsUpgradeSell ➝ Hold
12/7/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/10/2022Exane BNP ParibasDowngradeNeutral ➝ Underperform370.00
10/10/2022BNP ParibasDowngradeNeutral ➝ Underperform
9/14/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
4/29/2022Kepler Capital MarketsUpgradeReduce ➝ Hold
4/27/2022Nordea Equity ResearchUpgradeSell ➝ Hold
3/30/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
3/17/2022BarclaysLower Target510.00 ➝ 490.00
2/4/2022Credit Suisse GroupLower TargetUnderperform ➝ Underperform390.00 ➝ 360.00
10/29/2021CitigroupReiterated RatingNeutral
10/28/2021UBS GroupReiterated RatingSell
9/2/2021BarclaysReiterated RatingOverweight
8/23/2021Berenberg BankUpgradeHold ➝ Buy
8/16/2021Credit Suisse GroupReiterated RatingUnderperform
8/13/2021UBS GroupReiterated RatingSell
7/28/2021BarclaysReiterated RatingOverweight
7/14/2021UBS GroupReiterated RatingSell
5/10/2021BarclaysReiterated RatingOverweight
5/4/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/30/2021Berenberg BankReiterated RatingHold
4/28/2021UBS GroupReiterated RatingSell
4/28/2021Credit Suisse GroupReiterated RatingUnderperform
4/28/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
2/9/2021BarclaysReiterated RatingOverweight
2/3/2021Berenberg BankUpgradeSell ➝ Hold
1/26/2021DanskeUpgradeSell ➝ Hold
1/25/2021BarclaysUpgradeUnderweight ➝ Overweight
11/18/2020BarclaysReiterated RatingUnderweight
10/8/2020Berenberg BankDowngradeHold ➝ Sell
10/1/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
8/13/2020BarclaysReiterated RatingUnderweight
7/28/2020BarclaysInitiated CoverageUnderweight
7/8/2020UBS GroupReiterated RatingSell
7/2/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
5/12/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell
1/14/2020BNP ParibasDowngradeOutperform ➝ Neutral
1/7/2020The Goldman Sachs GroupInitiated CoverageBuy
12/17/2019Berenberg BankDowngradeBuy ➝ Hold
11/20/2019CitigroupUpgradeNeutral ➝ Buy
9/30/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
8/19/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
3/26/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
2/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy
2/5/2019Berenberg BankUpgradeHold ➝ Buy
1/30/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
1/28/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
12/20/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
10/30/2018JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Novozymes A/S logo
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $50.29
Low: $50.18
High: $51.16

50 Day Range

MA: $49.96
Low: $47.30
High: $52.94

52 Week Range

Now: $50.29
Low: $45.97
High: $71.14

Volume

12,383 shs

Average Volume

24,210 shs

Market Capitalization

$11.43 billion

P/E Ratio

27.14

Dividend Yield

1.16%

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Novozymes A/S?

The following Wall Street research analysts have issued research reports on Novozymes A/S in the last year: Barclays PLC, BNP Paribas, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DNB Markets, Exane BNP Paribas, Jefferies Financial Group Inc., JPMorgan Chase & Co., Kepler Capital Markets, and Nordea Equity Research.
View the latest analyst ratings for NVZMY.

What is the current price target for Novozymes A/S?

1 Wall Street analysts have set twelve-month price targets for Novozymes A/S in the last year. Their average twelve-month price target is $370.00, suggesting a possible upside of 635.7%. Exane BNP Paribas has the highest price target set, predicting NVZMY will reach $370.00 in the next twelve months. Exane BNP Paribas has the lowest price target set, forecasting a price of $370.00 for Novozymes A/S in the next year.
View the latest price targets for NVZMY.

What is the current consensus analyst rating for Novozymes A/S?

Novozymes A/S currently has 2 sell ratings, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVZMY, but not buy more shares or sell existing shares.
View the latest ratings for NVZMY.

What other companies compete with Novozymes A/S?

Other companies that are similar to Novozymes A/S include Celanese, Svenska Cellulosa Aktiebolaget SCA (publ), Yara International ASA, Suzano and Croda International. Learn More about companies similar to Novozymes A/S.

How do I contact Novozymes A/S's investor relations team?

Novozymes A/S's physical mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company's listed phone number is (454) 446-0000 and its investor relations email address is [email protected] The official website for Novozymes A/S is www.novozymes.com. Learn More about contacing Novozymes A/S investor relations.